About

 

SOLA Biosciences (Boston, MA) is a pre-clinical-stage biopharmaceutical company with a 10-years R&D history, focusing on developing transformative gene-therapies to treat conformational diseases such as Amyotrophic Lateral Sclerosis (ALS), Huntington's disease (HD), and Alzheimer’s disease (AD).

Technology

Engineered Targeting Chaperone Platform Technology (JUMP70) developed by SOLA to repair specific disease-causing misfolding proteins by using patient’s own chaperones

Pipeline

Ten (10) pipelines and more coming. The Flagship candidate SOL-257 is in the preclinical development for 2022 IND submission in the US.

Investment

Self-funded by an owner for 10 years, totaling $2.3M.  Eisai, Mitsubishi Tanabe, and UTEC invested $8.2M.  $15M Series A fundraising is in Progress.

Investors

Our Location

Contact Us

Currently no internship openings